Modulated chemo-hormonotherapy in advanced XXXX . A pilot study.

@entity1 @entity172 @entity4181 @entity137 @entity440 @entity0 @entity786 @entity1499 @entity1487
Twenty-two @entity1 with advanced @entity0 have been treated with sequential chemo-hormonotherapy consisting of @entity440 20 mg/day orally for 14 consecutive days, followed by no therapy for ten days, then @entity172 0.625 mg/day orally for three days; the next day @entity1499 200 mg/m2 i.v. and @entity786 600 mg/m2 i.v.; after 24 hours @entity4181 200 mg/m2 i.v. and @entity1487 600 mg/m2 i.v. Fifteen @entity1 were evaluable for response, 22 were evaluable for @entity137 . All but one were heavily pretreated with chemo and/or hormonotherapy. Nine of 15 had previously received palliative CMF ( @entity786 , @entity1499 , @entity1487 ) (mean 9 cycles), and one @entity1 12 cycles adjuvant CMF. Thirteen of 15 previously received @entity440 (median treatment of 18 months). Six @entity1 had multiple metastatic disease, while five had visceral involvement. They were all postmenopausal, with median age 57 years, and median disease-free interval 31 months. ER status was not known and the median ECOG performance status was 1. Overall response rate was 20%. Only one @entity1 attained complete remission; 46.6% were stable disease and 33.3% progressive disease. Accepting that the response rate is very low in pretreated @entity1 , this 20% can be significant. Ninety cycles were administered to 22 @entity1 and the treatment was very well tolerated: both hematologic and nonhematologic @entity137 were mild.
